ChemicalBook > Product Catalog >API >Synthetic Anti-infective Drugs >Antiviral drugs >Saquinavir

Saquinavir

Saquinavir Suppliers list
Company Name: BOC Sciences
Tel: 1-631-485-4226
Email: inquiry@bocsci.com
Products Intro: Product Name:Saquinavir
CAS:127779-20-8
Purity:>=98% Package:1g;USD
Company Name: HENAN BON INDUSTRIAL CO.,LTD
Tel: 0371-55170695
Email: info@hnbon.com
Products Intro: Product Name:Saquinavir
CAS:127779-20-8
Purity:0.99 Package:5KG;1KG;6806KG
Company Name: CONIER CHEM AND PHARMA LIMITED
Tel: 86-18523575427
Email: sales@conier.com
Products Intro: Product Name:saquinavir
CAS:127779-20-8
Purity:0.99 Package:1kg
Company Name: career henan chemical co
Tel: 0086-371-86658258
Email: factory@coreychem.com
Products Intro: Product Name:Saquinavir
CAS:127779-20-8
Purity:99% Package:1KG;USD
Company Name: Shaanxi Dideu Medichem Co. Ltd
Tel:
Email: 1012@dideu.com
Products Intro: Product Name:Saquinavir
CAS:127779-20-8
Purity:99% Package:1KG;0.01USD|25KG;0.1USD|200KG;1USD

Lastest Price from Saquinavir manufacturers

  • Saquinavir USP/EP/BP
  • US $1.10 / g
  • 2021-07-16
  • CAS:127779-20-8
  • Min. Order: 1g
  • Purity: 99.9%
  • Supply Ability: 100 Tons Min
  • Saquinavir
  • US $15.00-10.00 / KG
  • 2021-07-13
  • CAS:127779-20-8
  • Min. Order: 1KG
  • Purity: 99%+ HPLC
  • Supply Ability: Monthly supply of 1 ton
  • Saquinavir
  • US $15.00-10.00 / KG
  • 2021-07-10
  • CAS:127779-20-8
  • Min. Order: 1KG
  • Purity: 99%+ HPLC
  • Supply Ability: Monthly supply of 1 ton
Saquinavir Basic information
Product Name:Saquinavir
Synonyms:(3S)-N-tert-Butyl-2-[(2R,3S)-3-[N-(2-quinolinylcarbonyl)-3-carbamoylalanylamino]-2-hydroxy-4-phenylbutyl]-1,2,3,4,4aβ,5,6,7,8,8aβ-decahydroisoquinoline-3α-carboxamide;(4aS,8aβ)-N-tert-Butyldecahydro-2-[(2R,3S)-2-hydroxy-4-phenyl-3-[[(2S)-3-carbamoyl-2-(2-quinolinylcarbonylamino)propanoyl]amino]butyl]isoquinoline-3α-carboxamide;Saquinavir & Saquinavir Mesylate;ButanediaMide,N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-diMethylethyl)aMino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylMethyl)propyl]-2-[(2-quinolinylcarbonyl)aMino]-,(2S)-;2-[[2-METHYL-3-(TRIFLUOROMETHYL)PHENYL]AMINO]PYRIDINE-3-CARBOXYLIC ACID;(2S)-N-[(2S,3R)-4-[(3S,4AS,8AS)-3-(TERT-BUTYLCARBAMOYL)-3,4,4A,5,6,7,8,8A-OCTAHYDRO-1H-ISOQUINOLIN-2-YL]-3-HYDROXY-1-PHENYL-BUTAN-2-YL]-2-(QUINOLINE-2-CARBONYLAMINO)BUTANEDIAMIDE;FLUNIXIN;FLUNIXINE
CAS:127779-20-8
MF:C38H50N6O5
MW:670.84
EINECS:1806241-263-5
Product Categories:Saquinavir;Pharmaceutical;Active Pharmaceutical Ingredients;peptides;API
Mol File:127779-20-8.mol
Saquinavir Structure
Saquinavir Chemical Properties
alpha D20 -55.9° (c = 0.5 in methanol)
Boiling point 1015.0±65.0 °C(Predicted)
density 1.211±0.06 g/cm3(Predicted)
storage temp. Sealed in dry,Store in freezer, under -20°C
pka11.05±0.46(Predicted)
Water Solubility 35.8mg/L(25 ºC)
CAS DataBase Reference127779-20-8(CAS DataBase Reference)
Safety Information
Hazardous Substances Data127779-20-8(Hazardous Substances Data)
MSDS Information
Saquinavir Usage And Synthesis
DescriptionSaquinavir mesylate, the first HIV protease inhibitor to reach the market, was launched in the U.S.A.. It is indicated for use in combination with approved nucleoside analogs for the treatment of advanced HIV infection. Saquinavir, a transition state analog of Phe-Pro, is a very potent and competitive inhibitor of HIV-1 and HIV-2 proteases with high specificity. Saquinavir inhibits the last stage in the replication process of HIV and prevents virion maturation in both acute and chronically infected cells. Combination of saquinavir with the nucleoside analogs such as zidovudine (AZT) or/and zalcitabine which inhibit the enzyme reverse transcriptase and target at an earlier stage in the HIV replication process, shows a greater than additive effect in increase in CD4 cell counts and reduction in viral load, with the combination delaying the onset of resistance to either drug alone. Saquinavir is well tolerated alone and in combination with A n .
OriginatorRoche (Switzerland)
UsesAntiviral (HIV protease inhibitor).
DefinitionChEBI: An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin- (1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N2(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.
IndicationsSaquinavir is a potent inhibitor of HIV-1 and HIV-2 protease. Fortovase, a soft gel preparation of saquinavir, has largely replaced saquinavir mesylate capsules (Invirase) because it has improved bioavailability. Saquinavir is usually well tolerated and most frequently produces mild gastrointestinal side effects.
Brand nameFortovase (Roche).
Acquired resistanceResistance is associated with an amino acid substitution at position 48 in the HIV protease (G48V). An L90M mutation also confers resistance, as it does for most protease inhibitors. Saquinavir-resistant isolates from patients on long-term therapy often show cross-resistance to other protease inhibitors.
General DescriptionSaquinavir (Invirase) is well tolerated following oral administration.Absorption of saquinavir is poor but is increasedwith a fatty meal. The drug does not distribute intothe CSF, and it is approximately 98% bound to plasma proteins.Saquinavir is extensively metabolized by the firstpasseffect. Bioavailability is 4% from a hard capsule and12% to 15% from a soft capsule. Saquinavir lowers p24antigen levels in HIV-infected patients, elevates CD4+counts, and exerts a synergistic antiviral effect when combinedwith RT inhibitors such as AZT and ddC.Although HIV-1 resistance to saquinavir and other HIVPIs occurs in vivo, it is believed to be less stringent andless frequent than resistance to the RT inhibitors.Nevertheless,cross-resistance between different HIV PIsappears to be common and additive,suggesting thatusing combinations of inhibitors from this class would notconstitute rational prescribing. The drug should be used incombination with at least two other antiretroviral drugs tominimize resistance. Dosage forms are Invirase (hard capsule)and Fortovase (soft capsule).
Pharmaceutical ApplicationsA peptidomimetic protease inhibitor formulated as the mesylate for oral use.
PharmacokineticsOral absorption: c. 4%
Cmax 1200 mg thrice daily: c. 1–2.2 mg/L
Cmin 1200 mg thrice daily: c. 0.1–0.22 mg/L
Plasma half-life: c. 7–12 h
Volume of distribution: c. 700 L
Plasma protein binding: c. 98%
Absorption and distribution
It is poorly absorbed and penetrates poorly into the CNS. The semen:plasma ratio is 0.04. It is not known if it is distributed into human breast milk.
Metabolism and excretion
It is metabolized via CYP3A4, principally to mono- and dihydroxylated derivatives. Around 88% of the dose is excreted in feces and 1% in urine. Caution should be exercised in severe renal impairment and moderate hepatic impairment; use in decompensated hepatic impairment is contraindicated.
Clinical UseTreatment of HIV infection (in combination with other antiretroviral drugs)
Side effectsThe most frequently reported adverse effects include abdominal discomfort, diarrhea and nausea. Ritonavir-boosted saquinavir is associated with a dyslipidemic profile characteristic of those treated with a boosted protease inhibitor requiring 200 mg of the ritonavir ‘booster’.
Saquinavir Preparation Products And Raw materials
Raw materialsDCM-->Sodium chloride-->Hexane-->Sodium borohydride-->2-Butanone-->Pyrrole-->p-Toluenesulfonic acid monohydrate
Tag:Saquinavir(127779-20-8) Related Product Information
SAQUINAVIR MESYLATE 1,2,3,4-TETRAHYDROISOQUINOLINE Butylated hydroxyanisole Isoquinoline Quinoline Flunixin meglumine SAQUINAVIR, [3H]- SAQUINAVIR BASE RITONAVIR,SEQUINAVIR Saquinavir-D9 FLUNIXINE MEGLUMINE SALT SAQUINAVIR MESYLATE USP(CRM STANDARD) ALTRENOGEST AKOS 92058 SAQUINAVIR [3H(G)] AMPRENAVIR NELFINAVIR AMINO ACIDS